Literature DB >> 12099546

A comparative study of effects of antiproliferative drugs on human retinal pigment epithelial cells in vitro.

Wen-Chuan Wu1, Ying-Hsien Kao, Dan-Ning Hu.   

Abstract

The effects of various antiproliferative drugs have been tested in numerous cell types in vitro, but a comparison of effects of these drugs on cultured human retinal pigment epithelium (RPE) has not been reported. We studied the effects of four most widely used antiproliferative drugs (5-FU, daunomycin, mitomycin and dexamethasone) in a new in vitro model system (cultured human RPE). Various concentrations and exposure periods were tested in four human RPE cell lines. 5-FU showed a dose-dependant growth inhibition, with an ID50 of 5.35 +/- 2.38 x 10(-7) M after 4 days culture. A decrease of cell number occurred relatively later, the slope of the dose-response curve was less steep than that of others. Mitomycin C showed an immediate and strong growth inhibition and cytotoxic effects, with an ID50 of 3.73 +/- 0.71 X 10(-9) M. RPE cultured with daunomycin showed an abrupt decrease of cell number from 10(-9) M to 10(-8) M, the ID50 value was 1.07 +/- 0.23 x 10(-8) M. Dexamethasone showed a biphasic effect; it stimulated cell growth at 10(-7) to 10-6 M and inhibited cell growth at 10(-4) M or higher, with an ID50 of 6.05 +/- 1.61 x 10(-3) M. The advantages and disadvantages of these drugs and the prospective clinical application of these drugs for management of proliferative vitreoretinopathy (PVR) were discussed. Development of an in vitro model using cultured human RPE to study the effects of various antiproliferative drugs can provide a rapid, safe and inexpensive method for selection of drugs used for management of proliferative vitreoretinopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12099546     DOI: 10.1089/108076802760116179

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  8 in total

Review 1.  Strategies to influence PVR development.

Authors:  Bernd Kirchhof
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08-10       Impact factor: 3.117

2.  Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.

Authors:  Justus G Garweg; Maria Wegmann-Burns; David Goldblum
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-10       Impact factor: 3.117

3.  Cell viability effects of triamcinolone acetonide and preservative vehicle formulations.

Authors:  S Shaikh; S Ho; L A Engelmann; S W Klemann
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

Review 4.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

5.  The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial.

Authors:  Ernesto Bali; Eric J Feron; Ed Peperkamp; Marc Veckeneer; Paul G Mulder; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-25       Impact factor: 3.117

Review 6.  Mitomycin: clinical applications in ophthalmic practice.

Authors:  Lekha M Abraham; Dinesh Selva; Robert Casson; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Intraocular application of Mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries.

Authors:  Alexandre Assi; Ziad Khoueir; Charles Helou; Henry Fakhoury; Georges Cherfan
Journal:  Eye (Lond)       Date:  2019-03-27       Impact factor: 3.775

8.  Modulated release from implantable ocular silicone oil tamponade drug reservoirs.

Authors:  Helen Cauldbeck; Maude Le Hellaye; Tom O McDonald; Mark Long; Rachel L Williams; Steve P Rannard; Victoria R Kearns
Journal:  J Polym Sci A Polym Chem       Date:  2018-02-09       Impact factor: 2.702

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.